Turn Biotechnologies Enhances Epigenetic Therapy with ARMMs Technology Acquisition

Turn Biotechnologies Acquires ARMMs Technology

In a significant move to strengthen its position in the field of epigenetic reprogramming, Turn Biotechnologies has announced its acquisition of the innovative ARMMs (ARRDC1 Mediated Microvesicles) technology. This advancement is anticipated to enhance the company's ability to deliver epigenetic therapies more effectively to specific tissues, thereby broadening the scope of its medical applications.

What are ARMMs?

ARMMs represent a breakthrough in precision medicine, facilitating targeted, non-viral vesicular delivery of therapeutic agents. This technology enables the delivery of larger and more diverse cargo, including gene editors and RNA-based therapies, a crucial asset for developing effective treatments in various areas such as ophthalmology, dermatology, and immunotherapy.

Collaboration with Harvard University

Turn Biotechnologies acquired licensing rights for ARMMs from Harvard University, along with associated assets from Vesigen Therapeutics based in Cambridge, Massachusetts. This acquisition is poised to expand the reach of Turn Bio’s eTurna® LNP (lipid nanoparticle) delivery platform, significantly enhancing the versatility and effectiveness of their epigenetic therapies, known as ERA® technology, which leverages mRNA to restore cellular function and combat age-related conditions.

Implications for Future Therapies

The integration of ARMMs technology into Turn’s existing platforms is a game-changer for its developmental pipeline, particularly for candidate drugs targeting age-related ailments. It allows for precise drug delivery at desired tissue sites, optimizing therapeutic outcomes and reducing potential unwanted side effects. The technology's ability to encapsulate various epigenetic modulators efficiently underscores its role in the future of regenerative medicine.

CEO Anja Krammer emphasized the importance of ARMMs in the company's mission to harness the potential of epigenetics. She stated, "This technology allows us to administer our therapies with unprecedented precision when and where they are needed, while also enabling us to deliver larger and more diverse therapeutic cargo effectively."

Interest from Investors

The groundbreaking nature of ARMMs technology has already captured the attention of major investors, including Bayer Healthcare LLC, Morningside Group Ltd., and Alexandria Ventures. Their interest highlights the forward-looking potential of this technology in reshaping therapeutic strategies in the healthcare sector.

Overview of Epigenetic Reprogramming

Turn Biotechnologies concentrates on reverting the epigenome to a younger, more functional state, which plays a critical role in treating diseases related to aging and other conditions where epigenetic factors are essential. This approach potentially allows for modulation of gene expression necessary for correcting or restoring normal cellular function in various age-related disorders such as skin aging, vision loss, muscle atrophy, joint degeneration, and more.

The ARMMs Delivery Framework

The ARMMs platform utilizes human extracellular vesicles to transport signaling molecules between cells, acting as a highly efficient system for delivering therapeutic compounds. Developed by Vesigen Therapeutics under Harvard's license, these vesicles are tailored to transport therapeutic materials into cells, rendering them an optimal solution for epigenetic interventions. The ARMMs technology distinguishes itself by targeting specific cell types, vastly minimizing off-target effects and improving the likelihood of successful treatment outcomes.

The compatibility and scalability of the ARMMs system enable Turn Bio to push the boundaries of what's currently possible with drug delivery, making significant strides towards addressing complex health issues associated with aging and tissue regeneration.

Conclusion

Turn Biotechnologies continues to lead the charge in epigenetic therapy advancements, and with the integration of ARMMs technology, the company is poised to redefine precision medicine timing as it capitalizes on this groundbreaking application. As preclinical studies advance, the potential benefits of this technology will resonate throughout various medical fields, ultimately leading to improved patient outcomes in revitalizing age-related therapies.

About Turn Biotechnologies

Turn Biotechnologies is a preclinical-stage company committed to developing transformative tissue restoration therapies at the cellular level. Their preclinical research primarily focuses on dermatological, ophthalmological, and immunological applications, aiming to address conditions such as osteoarthritis and muscle disorders. For more information, visit www.turn.bio.